Leadership opportunity in functional genomics, pharmacogenomics, and personalized therapeutics at The Ohio State University College of Medicine
The College of Medicine at the Wexner Ohio State Medical Center plans significant expansion in genomics and personalized medicine. Building on an existing College of Medicine Center for Pharmacogenomics, a new leader will have the opportunity to build a substantial group of investigators covering all aspects of genetics and genomics, with a strong clinical translational component, exemplified in pharmacogenomics and personalized therapeutics. While cancer has been an area of strength at OSU, several new initiatives and recruitment strategies are ongoing in multiple medical disciplines, each in need of broad genomics expertise to integrate existing resources with new focused studies.
I here solicit informal requests or recommendations for any senior investigators, or advanced mid-level scientists, who want to explore this unique opportunity. Please address confidential inquiries or recommendations to:
Wolfgang Sadee, Dr.rer.nat.
Felts Mercer Professor of Medicine and Pharmacology
Vice Chair, Department of Cancer Biology and Genetics
Director, College of Medicine Center for Pharmacogenomics
1004 BRT, 460 W 12th Avenue
The Ohio State University
Columbus OH 43210
tel. 614-330 0509 (cell)
PGRN members are invited to participate in a survey about the future of the PGRN. The NIH (which is our only source of financial support), will no longer support the PGRN after June 2020. We are exploring options that will allow the PGRN to continue to exist as part of another organization, and would like to hear from our members which PGRN services and activities are most important. This survey should take no longer than 10 minutes to complete. We hope that you take the time to complete this important survey by Friday, May 17.
The ASHG abstract submission site for the 2019 ASHG Annual Meeting in Houston on October 15-19, 2019 is now open. There is an abstract topic of “Precision Medicine, Pharmacogenomics, and Genetic Therapies” that pharmacogenomics researchers may be interested in. The abstract submission deadline is June 6, 2019 at 8 pm Eastern time.
A team of researchers from the UK (University of Liverpool; University of St. Andrews; Cochrane Editorial Unit, London) are currently developing the “STrengthening the Reporting Of Pharmacogenetic Studies” (STROPS) reporting guideline in order to improve the reporting of pharmacogenetic studies, and to facilitate the conduct of high-quality systematic reviews and meta-analyses. They are conducting a Delphi survey to gain consensus opinion on which reporting items ought to be included in this guideline and are looking for participants to participate in a survey.
The Delphi survey will consist of two rounds of electronic-based survey, response and feedback. In the first round survey, participants will be asked to score reporting items based on their opinions about the importance of these items for inclusion in the reporting guideline. In the second round survey, a summary of responses from the first round will be provided, and participants will be asked to re-score the reporting items. Any additional reporting items identified by participants in the first round will be included for scoring by participants in the second round of the Delphi survey. Completion of the first round survey does not necessitate completion in the second round survey. All scoring data will be anonymized. This survey will take approximately 60-90 minutes to complete.
If you would like to participate in the development of this reporting guideline, please complete the first round of the Delphi survey by Friday, May 3 at the link below.
The PsychPGx Lab at the University of Calgary is currently accepting applications for a highly motivated Postdoctoral Scholar in Pharmacogenomics with a strong background in genomics/bioinformatics/computational biology/human molecular genetics to help analyze whole genome sequencing data to discover genetic variants associated with response to psychiatric medications.
The PGRN Hub congratulates the Best Trainee Abstract Award winners from the Pharmacogenomics Poster Session at the 2019 ASCPT Annual Meeting.
Best Trainee Abstract Award Winners
In addition, we also recognize the following trainees for Honorable Mention: Zachary Taylor (Cincinnati Children’s Hospital) and Maaike van der Lee (Leiden University).
We congratulate all participants for their excellent presentations of cutting-edge pharmacogenomics research.
The African American Pharmacogenomic Consortium Network Transdisciplinary Collaborative Center (ACCOuNT TCC) was created to: 1) establish an African Ancestry pharmacogenomics research network to facilitate genomic research and to establish a public genomics resource for continued translational research; 2) establish mechanisms to support implementation, diffusion, and continuing evaluation and improvement of precision medicine in African Americans; and 3) engage community leaders in African American pharmacogenomic research. As part of this commitment, ACCOuNT will provide funding for a pilot grant program that will accelerate the uptake of cardiovascular pharmacogenomics research findings among community physicians and patients. Two projects focused on African American cardiovascular pharmacogenomics, or how a person’s genes impact their reaction to drugs for the heart and blood vessels, will be awarded each year. Awards will be made for up to $25,000 for each project. Applications are due on Friday, March 22, 2019.
The Clinical Pharmacogenetics Implementation Consortium (CPIC®) Meeting will be held in Memphis, TN at St. Jude Children’s Research Hospital on June 6th (full day) and June 7th (1/2 day). CPE and CME will be offered. Information, including registration and hotel information, is available here. Early bird registration is now open and is $75.00. The deadline is April 1, 2019. Regular registration will open April 2, 2019 and is $150.00. The deadline is May 1, 2019.
The Pharmacogene Variation (PharmVar) Consortium is the successor of the Human Cytochrome P450 (CYP) Allele Nomenclature website that served the pharmacogenetics community by designating CYP
star (*) alleles. The aim of PharmVar is to continue the mission of serving as an official allele designation authority for the global pharmacogenetics community. Herein, we describe the introduction of the first non-CYP gene to PharmVar. Pharmacogenetic variation of NUDT15 plays a significant role in thiopurine response variability and toxicity.
The Hub team